Aarkstore announce a new report "The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis" through its vast collection of market research report.
Summary
The leading business intelligence provider, has released its latest research “The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis.” The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global respiratory diseases therapeutics market. The report analyzes the markets for respiratory disease therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.
Scope
The scope of this report includes:
Annualized market data for the respiratory diseases therapeutics market from 2000 to 2008, forecast forward to 2015
Analysis of the leading therapeutic segments including asthma, chronic obstructive pulmonary disease (COPD), pulmonary hypertension and cystic fibrosis
Analysis of the respiratory diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
Market characterization of the respiratory diseases therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
Key drivers and barriers that have a significant impact on the market
Coverage of pipeline molecules in various phases of drug development
Competitive benchmarking of leading companies. The key companies studied in this report are Novartis AG, AstraZeneca and Merck & Co
Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global respiratory diseases therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to
Align product portfolio to the markets with high growth potential
Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
Develop key strategic initiatives by understanding key focus areas of leading companies
Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps
For more information, please visit :
http://www.aarkstore.com/reports/The-Future-of-Respiratory-Diseases-Therapeutics-Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis-34883.html
Or email us at press@aarkstore.com or call +919272852585
Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers. Our customers include more than 700 leading financial institutions, professional service firms, consulting, law and accounting firms and other corporations throughout the world.
